Press Announcements > FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas

Press Announcements > FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas

06/29/2017 04:44 PM EDT

The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).